CRIS Current Research Information System

CATANI, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.120
AS - Asia 5.447
EU - Europa 3.606
SA - Sud America 389
AF - Africa 294
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 15.869
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.021
VN - Vietnam 1.647
SG - Singapore 1.492
CN - Cina 1.151
GB - Regno Unito 783
IT - Italia 693
SE - Svezia 558
DE - Germania 453
HK - Hong Kong 373
BR - Brasile 299
IN - India 257
FR - Francia 236
IE - Irlanda 172
RU - Federazione Russa 168
NL - Olanda 94
FI - Finlandia 88
JP - Giappone 77
TG - Togo 74
UA - Ucraina 73
ZA - Sudafrica 73
KR - Corea 71
CI - Costa d'Avorio 63
CA - Canada 60
EE - Estonia 59
BG - Bulgaria 52
JO - Giordania 50
CH - Svizzera 43
BD - Bangladesh 42
BE - Belgio 40
PH - Filippine 37
TR - Turchia 35
TW - Taiwan 33
AR - Argentina 29
TH - Thailandia 29
ID - Indonesia 26
NG - Nigeria 24
IQ - Iraq 22
IR - Iran 21
EC - Ecuador 19
MX - Messico 17
AT - Austria 16
SA - Arabia Saudita 16
PL - Polonia 15
MY - Malesia 13
SC - Seychelles 13
ES - Italia 11
PK - Pakistan 11
AU - Australia 10
VE - Venezuela 10
CO - Colombia 9
LT - Lituania 9
UZ - Uzbekistan 8
CZ - Repubblica Ceca 7
DZ - Algeria 7
LB - Libano 7
MA - Marocco 7
CL - Cile 6
CR - Costa Rica 6
EG - Egitto 6
PE - Perù 6
ET - Etiopia 5
GR - Grecia 5
PY - Paraguay 5
RO - Romania 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
HR - Croazia 4
LV - Lettonia 4
OM - Oman 4
AO - Angola 3
BO - Bolivia 3
IL - Israele 3
JM - Giamaica 3
KE - Kenya 3
KZ - Kazakistan 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
AL - Albania 2
CG - Congo 2
CY - Cipro 2
GH - Ghana 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
KG - Kirghizistan 2
NI - Nicaragua 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
SN - Senegal 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
BS - Bahamas 1
BW - Botswana 1
DK - Danimarca 1
GA - Gabon 1
Totale 15.855
Salva come PNG Salva come JPEG
Città #
Singapore 1.007
Ashburn 693
Southend 663
Fairfield 535
San Jose 534
Chandler 524
Ho Chi Minh City 356
Hong Kong 352
Hanoi 279
Dong Ket 263
Woodbridge 237
Seattle 230
Houston 229
Wilmington 220
Cambridge 216
Ann Arbor 195
Santa Clara 195
Beijing 187
Dublin 171
Princeton 171
Boardman 151
Bologna 143
Hefei 94
Los Angeles 93
Lauterbourg 85
Dallas 84
New York 84
Lomé 74
Milan 72
Helsinki 68
Nanjing 68
Westminster 66
Abidjan 63
Tokyo 62
Padova 56
Bremen 54
Seoul 51
Amman 50
Redmond 50
Sofia 50
Jinan 49
Haiphong 48
Munich 47
Da Nang 44
Shenyang 43
Turin 42
Berlin 40
Brussels 40
Council Bluffs 39
Buffalo 36
Hyderabad 34
Bern 33
São Paulo 33
Cornaredo 32
Redondo Beach 32
San Diego 31
Saint Petersburg 30
Florence 29
Guangzhou 29
Frankfurt am Main 24
Jacksonville 24
Zhengzhou 23
Toronto 22
Abeokuta 21
London 21
Medford 20
Orem 20
Shanghai 20
Rome 19
Biên Hòa 18
Nanchang 18
Burdur 17
Changsha 17
Redwood City 17
Can Tho 16
Falls Church 16
Hebei 16
Hangzhou 15
San Francisco 15
Hải Dương 14
Norwalk 14
Taiyuan 14
Turku 14
Chicago 13
Des Moines 13
Paris 13
Phoenix 13
Quận Bình Thạnh 13
Tianjin 13
Boston 12
Brooklyn 12
Bình Phước 12
Fremont 12
Johannesburg 12
Stockholm 12
Dearborn 11
Jakarta 11
Kuala Lumpur 11
Shenzhen 11
The Dalles 11
Totale 10.126
Salva come PNG Salva come JPEG
Nome #
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 310
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 262
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 239
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 227
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 224
A novel model of CCl4-induced cirrosi with ascites in the mouse. 224
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 222
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 219
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 214
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 213
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 213
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 211
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 209
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 209
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 207
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 205
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 204
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 198
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 198
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 194
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 194
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 190
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 188
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 186
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 185
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 185
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 185
Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia 184
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 184
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 184
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy 184
Platelet lysate enhances the therapeutic activity of Adipose Derived Mesenchymal stromal cells isolated from Crohn disease patients in a novel Mouse model of Colitis 184
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 180
Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability 179
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 179
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 179
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function 178
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 176
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: a phase I clinical trial 170
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 170
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 168
The “vesicular intelligence” strategy of blood cancers 168
Stem cell mobilization and collection in patients with liver cirrhosis. 165
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 164
Increased transcription of mitochondrial genes for Complex I in human platelets during ageing 164
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 164
SuperB: A High-Luminosity Asymmetric e+ e- Super Flavor Factory. Conceptual Design Report 163
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 162
CD 133+ stem cells for the treatment of end stage liver disease. 160
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 157
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 156
INFLAMMATORY PATHWAYS IN THE BONE MARROW: ROLE OF TIMP-1 IN HEMATOPOIETIC STEM/PROGENITOR CELLS AND LEUKEMIA 149
The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engrftment. 147
Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product 147
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 144
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 143
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 141
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 141
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 139
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 137
The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis 134
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). 134
Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura. 133
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 132
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. 131
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 129
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 129
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 127
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study 125
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 124
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge 122
The CD47 pathway is deregulated in human immune thrombocytopenia 114
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia 112
Low-dose methotrexate as treatment of myeloproliferative neoplasms: Proof of principle of clinical activity 109
null 107
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 107
CD133+ hematopoietic stem cells reinfusion in end-stage liver disease (ESLD): final results of a phase I clinical trial 106
The power of extracellular vesicles in myeloproliferative neoplasms: “Crafting” a microenvironment that matters 106
CD133+ stem cells for the treatment of end-stage liver disease 104
Human T-lymphocyte-derived megakaryocyte colony-stimulating activity 101
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 99
null 98
SPONTANEOUS MOBILIZATIONOF BONE MARROW-DERIVED HEMATOPOIETIC AND ENDOTHELAIL PROGENITOR CELLS AFTER ORTHOTOPIC LIVER TRANSPALNTATION (OLT). 97
null 96
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 94
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years 93
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis 91
Reinfusion of highly purified CD133+ stem cells in patients with end-stage liver disease (ESLD): final results of a phase I clinical trial 87
null 86
Is there a gender effect in polycythemia vera? 83
Single-Cell Metabolic Profiling Integrated with Extracellular Vesicle Analysis Reveals Novel Metabolic Vulnerabilities and Prognostic Biomarkers in Acute Myeloid Leukemia 79
Hollow fiber flow field-flow fractionation enables high-quality Extracellular Vesicle isolation from minimal plasma samples in polycythemia vera liquid biopsy 77
null 68
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation 66
Cancer procoagulant in acute non lymphoid leukemia: Relationship of enzyme detection to disease activity 56
A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase 55
Ascorbic acid for the treatment of chronic refractory idiopathic thrombocytopenic purpura (ITP) 52
Increased P-selectin plasma levels in patients with thrombotic thrombocytopenic purpura 52
Ticlopidine in the treatment of thrombotic thrombocytopenic purpura: Report of two cases 44
Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides 42
Totale 15.026
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.408
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.408
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021504 0 0 0 0 0 0 0 0 0 0 48 456
2021/20221.829 118 92 91 194 140 68 48 125 60 203 378 312
2022/20232.094 210 293 120 276 121 175 50 157 367 78 143 104
2023/2024601 48 96 41 75 53 126 27 33 15 41 22 24
2024/20252.286 120 265 205 212 340 113 147 80 86 157 106 455
2025/20265.528 489 445 492 338 582 242 487 420 1.340 563 130 0
Totale 16.198